105
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Two different del(5q) clones in a patient with myelodysplastic syndrome

, , , , , & show all
Pages 1811-1814 | Received 17 Feb 2011, Accepted 13 Mar 2011, Published online: 10 Jun 2011

References

  • Silverman LR. Neoplasms of the hematopoietic system: myelodysplastic syndrome. In: Holland J, Frei EI, Bast RJ, editors.Cancer medicine. BC Decker;Hamilton, Canada: 2000. pp1931–1946.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
  • List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549–557.
  • Haase D, Germing U, Schanz J, et al. New insights into prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–4395.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid Tissues. Lyon, France: IARC; 2008.
  • Haase D, Feuring-Buske M, Könemann S, et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 1995;86:2906–2912.
  • Mitelman F. An International System for Human Cytogenetic Nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: S. Karger AG; 1995.
  • Weise A, Mrasek K, Fickelscher I, et al. Molecular definitionof high-resolution multicolor banding probes: firstwithin the human DNA sequence anchored FISHbanding probe set. JHistochem Cytochem 2008;56: 487–493.
  • Braulke F, Schanz J, Jung K, et al. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. Leuk Res 2010;34:1296–1301.
  • Van den Berghe H, Cassiman JJ, David G, Fryns JP, MichauxJL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974;251: 437–438.
  • Giagounidis AAN, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including q31. Leukemia 2004;18:113–119.
  • Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994;84:3253–3260.
  • Boultwood J, Fidler C, Lewis S, et al. Molecular mapping ofuncharacteristically small 5q deletions in two patients with the 5q-syndrome: delineation of the critical region on 5q andidentification of a 5q-breakpoint. Genomics 1994;19:425–432.
  • Haferlach C, Bacher U, Tiu R, Maciejewski P, List A. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genet Cytogenet 2008;187:101–111.
  • Nagarajan L, Lange B, Cannizzaro L, Finan J, Nowell PC, Huebner K. Molecular anatomy of a 5q interstitial deletion. Blood 1990;75:82–87.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.